Patents by Inventor Xiaoju (Max) Ma

Xiaoju (Max) Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10260102
    Abstract: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: April 16, 2019
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Xiaoju Max Ma, Chitra Manohar, Alison Tsan
  • Patent number: 10253349
    Abstract: Provided herein are methods and compositions for detecting gene fusions, e.g., relevant to cancer. The present methods and compositions can be used to detect gene fusions with very high sensitivity and specificity. The present methods and compositions can detect gene fusions, e.g., in free circulating tumor RNA from a plasma sample.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 9, 2019
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Ann Begovich, Rajiv Dua, Dwight Kuo, Xiaoju Max Ma, Ellen Ordinario
  • Publication number: 20180346994
    Abstract: Provided herein are methods and compositions for multiplex detection of a large number of actionable gene fusions with very high sensitivity and specificity. The present methods and compositions can detect ALK, RET, and ROS1 gene fusions, optionally in combination with other mutations and fusions.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Inventors: Ann Begovich, Cindy Cheung, Javelin Chi, Grantland Hillman, Dwight Kuo, Michael Lee, Chitra Manohar, Xiaoju Max Ma, Ellen Ordinario, Jaya Rajamani, Huan Truong
  • Patent number: 10127351
    Abstract: Accurate and fast mapping of sequencing reads obtained from a targeted sequencing procedure can be provided. Once a target region is selected, alternate regions of the genome that are sufficiently similar to the target region can be identified. If a sequencing read is more similar to the target region than to an alternate region, then the read can be determined as aligning to the target region. The reads aligning to the target region can then be analyzed to determine whether a mutation exists in the target region. Accordingly, a sequencing read can be compared to the target region and the corresponding alternate regions, and not to the entire genome, thereby providing computational efficiency.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: November 13, 2018
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Xiaoying Chen, Yan Li, Wei-Min Liu, Xiaoju (Max) Ma, Sim-Jasmine Truong
  • Publication number: 20170327887
    Abstract: Provided herein are methods and compositions to detect MET exon 14 skipping using RT-PCR, and methods of treating individuals with MET exon 14 deleted cancers.
    Type: Application
    Filed: May 11, 2017
    Publication date: November 16, 2017
    Inventors: Cindy Cheung, Grantland Hillman, Xiaoju Max Ma, Chitra Manohar, Lily Wong
  • Publication number: 20160304937
    Abstract: Provided herein are methods and compositions for detecting gene fusions, e.g., relevant to cancer. The present methods and compositions can be used to detect gene fusions with very high sensitivity and specificity. The present methods and compositions can detect gene fusions, e.g., in free circulating tumor RNA from a plasma sample.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Inventors: Ann Begovich, Rajiv Dua, Dwight Kuo, Xiaoju Max Ma, Ellen Ordinario
  • Publication number: 20160092630
    Abstract: Accurate and fast mapping of sequencing reads obtained from a targeted sequencing procedure can be provided. Once a target region is selected, alternate regions of the genome that are sufficiently similar to the target region can be identified. If a sequencing read is more similar to the target region than to an alternate region, then the read can be determined as aligning to the target region. The reads aligning to the target region can then be analyzed to determine whether a mutation exists in the target region. Accordingly, a sequencing read can be compared to the target region and the corresponding alternate regions, and not to the entire genome, thereby providing computational efficiency.
    Type: Application
    Filed: November 30, 2015
    Publication date: March 31, 2016
    Inventors: Xiaoying Chen, Yan Li, Wei-Min Liu, Xiaoju (Max) Ma, Sim-Jasmine Truong
  • Patent number: 9218450
    Abstract: Accurate and fast mapping of sequencing reads obtained from a targeted sequencing procedure can be provided. Once a target region is selected, alternate regions of the genome that are sufficiently similar to the target region can be identified. If a sequencing read is more similar to the target region than to an alternate region, then the read can be determined as aligning to the target region. The reads aligning to the target region can then be analyzed to determine whether a mutation exists in the target region. Accordingly, a sequencing read can be compared to the target region and the corresponding alternate regions, and not to the entire genome, thereby providing computational efficiency.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: December 22, 2015
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Xiaoying Chen, Yan Li, Wei-Min Liu, Xiaoju (Max) Ma, Sim-Jasmine Truong
  • Publication number: 20150099747
    Abstract: The invention comprises reagents and methods for detecting cancer-associated mutations in the human EZH2 gene. Further, a method of detecting the mutations and a method of treatment are disclosed.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 9, 2015
    Inventors: Xiaoju Max Ma, Chitra Manohar, Alison Tsan
  • Publication number: 20140149049
    Abstract: Accurate and fast mapping of sequencing reads obtained from a targeted sequencing procedure can be provided. Once a target region is selected, alternate regions of the genome that are sufficiently similar to the target region can be identified. If a sequencing read is more similar to the target region than to an alternate region, then the read can be determined as aligning to the target region. The reads aligning to the target region can then be analyzed to determine whether a mutation exists in the target region. Accordingly, a sequencing read can be compared to the target region and the corresponding alternate regions, and not to the entire genome, thereby providing computational efficiency.
    Type: Application
    Filed: November 29, 2012
    Publication date: May 29, 2014
    Applicant: Roche Molecular Systems, Inc.
    Inventors: Xiaoying Chen, Yan Li, Wei-Min Liu, Xiaoju (Max) Ma, Sim-Jasmine Truong